M&T Bank Corp Has $34.43 Million Position in Bristol Myers Squibb Company $BMY

M&T Bank Corp lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 6.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 763,376 shares of the biopharmaceutical company’s stock after selling 49,299 shares during the quarter. M&T Bank Corp’s holdings in Bristol Myers Squibb were worth $34,429,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Ossiam lifted its position in shares of Bristol Myers Squibb by 18.0% during the 3rd quarter. Ossiam now owns 51,042 shares of the biopharmaceutical company’s stock worth $2,302,000 after buying an additional 7,781 shares during the period. Marathon Capital Management lifted its holdings in shares of Bristol Myers Squibb by 9.7% during the third quarter. Marathon Capital Management now owns 8,564 shares of the biopharmaceutical company’s stock valued at $386,000 after acquiring an additional 755 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at $2,357,000. Bank of Hawaii boosted its stake in shares of Bristol Myers Squibb by 6.0% in the 3rd quarter. Bank of Hawaii now owns 16,143 shares of the biopharmaceutical company’s stock valued at $728,000 after purchasing an additional 912 shares in the last quarter. Finally, NorthRock Partners LLC grew its holdings in shares of Bristol Myers Squibb by 18.9% in the 3rd quarter. NorthRock Partners LLC now owns 32,902 shares of the biopharmaceutical company’s stock worth $1,484,000 after purchasing an additional 5,226 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.1%

Bristol Myers Squibb stock opened at $59.02 on Friday. The firm has a market capitalization of $120.18 billion, a price-to-earnings ratio of 17.11, a PEG ratio of 0.17 and a beta of 0.26. The company’s 50 day simple moving average is $58.24 and its 200 day simple moving average is $51.40. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the business posted $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analysts Set New Price Targets

BMY has been the subject of several analyst reports. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. HSBC reaffirmed a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Scotiabank reissued a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Truist Financial set a $65.00 price target on Bristol Myers Squibb in a report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.